A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Aura Biosciences
- Study ID
- NCT06007690
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Choroidal Melanoma
- Indeterminate Lesions
- Ocular Melanoma
- Uveal Melanoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Bel-sar — DRUGBel-sar via suprachoroidal administration followed by laser application.
- Suprachoroidal Microinjector — DEVICESuprachoroidal injection device
- Infrared Laser — DEVICELaser application
- Sham Infrared Laser — DEVICESham laser application
- Sham Microinjector — DEVICESham injection device
Study Details
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
Key Dates
- Start date
- Dec 6, 2023
- Status verified
- Feb 2026
- Primary completion
- Nov 15, 2027
- Completion
- Aug 15, 2028
Study Design
- Enrollment
- 100 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: High dose bel-sar treatment arm & laser applicationHigh dose of bel-sar + laser application
- Experimental: Low dose bel-sar treatment arm & laser applicationLow dose of bel-sar + laser application
- Sham Comparator: Sham control arm & sham laserSham injection + sham laser
Primary Outcome Measure
Time to reach tumor progression [ Time Frame: 65 weeks ]
Central Contacts
- Medical Monitor617-500-8864
Locations (36)
Find similar trials in Birmingham, AL
By research site
Retina Consultants of Alabama· Birmingham, ALUCSD Shiley Eye Institute, Jacobs Retina Center· La Jolla, CADoris Stein Eye Research Center· Los Angeles, CAStanford University School of Medicine· Palo Alto, CARetinal Consultants Medical Group, Inc.· Sacramento, CABascom Palmer Eye Institute· Miami, FL
Related Studies
- Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid TumorsPHASE1 · Recruiting · Anusha Kalbasi · Duarte, California
- Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition SyndromeRecruiting · Mohamed Abdel-Rahman · Columbus, Ohio
- Olaparib in Combination With Pembrolizumab for Advanced Uveal MelanomaPHASE2 · Recruiting · H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida
- A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated LiposarcomaPHASE1 · Recruiting · Memorial Sloan Kettering Cancer Center · Harrison, New York